TDNet Discover

Objective: The objective of this study was to determine if there are long term morbidities or mortality in renally impaired patients with the use of IV contrast-enhanced studies. Methods: A detailed systematic review was conducted to gather information regarding the effects of non-contrast-enhanced and contrast-enhanced imaging studies on renal function in renally impaired patients, and whether these effects, if any, have long-term morbidities or mortality associated with them. A quality assessment and data extraction were conducted on all articles accepted by the researchers. Six out of the ten articles were determined to be eligible and were included in this research. Results: After reviewing and comparing the results of the included articles, it can be concluded that contrast-induced nephropathy is more likely to occur in patients who have increased serum creatinine along with other risk factors, such as hypertension and type 2 diabetes mellitus. The probability of developing CIN, according to the data collected, is 9.95%. In contrast, data analysis demonstrated only 2.62% of patients will have long term sequela from the use of contrast medium. Conclusion: Our research indicates that the rate of long-term adverse events in renally impaired patient after IV contrast is 2.62%. This indicates that most patients recover fully recover from any adverse events associated with the use of contrast. A study by Castaldo, P (2019), has shown that with the use of 0.9% normal saline (1.0-1.5mL/kg/h), given prophylactically prior to the use of IV contrast medium, aided in the prevention of CIN in patients with CKD stages III and IV. In addition, because of an unclear mechanism and compounding factors, it is unclear what portion of these long-term adverse events are exclusively caused by IV contrast. Further studies are required to determine the direct link between IV contrast and longer-term adverse outcomes.